Symptom management in ALS. David Walk, M.D. Medical Director ALS Certified Center of Excellence University of Minnesota Health

Similar documents
Annette Edwards Consultant in Palliative Medicine

Amyotrophic Lateral Sclerosis: Current Understanding and Future Prospects

20/11/2013. Dr. Sinead Maguire Neurology Registrar 22 nd November 2013

THE PALLIATION OF AMYOTROPHIC LATERAL SCLEROSIS. Fiona Punter MD, PhD, FRCPC

MOTOR NEURONE DISEASE

ROLE OF THE DIETITIAN. Aims of Dietetic Treatment NUTRITIONAL ISSUES WHY? MALNUTRITION NUTRITONAL MANAGEMENT OF MOTOR NEURONE DISEASE.

Radicava (edaravone)

ALS: Evolution of disease conception and the need for multidisciplinary care. Dan Larriviere MD, JD, FAAN Director, Ochsner ALS Clinic

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

RESPIRATORY PROBLEMS IN MND RICHARD HARRISON MND RESPIRATORY ASSESSMENT SERVICE LUNG HEALTH UNIVERSITY HOSPITAL OF NORTH TEES

Palliative care in Neurology from the real experience

2: Symptoms and management

MOTOR NEURONE DISEASE RESPIRATORY ISSUES

Symptom management. ALS and Symptom Management. Impacts continued. Psychosocial Impacts 3/22/2012. Cognitive and Behavioral Impairments

Palliative care in Neurology from the real experience

National Stroke Association s Guide to Choosing Stroke. Rehabilitation Services

Speech Therapy Care in ALS. Brittney Skidmore, MS, CCC-SLP

Getting Comfortable with Managing Pain and Pressure Care in individuals with Motor Neuron Disease Stephanie Williams Occupational Therapist

Respiratory Management of Facioscapulohumeral Muscular Dystrophy. Nicholas S. Hill, MD Tufts Medical Center Boston, MA

Motor Neurone Disease NICE to manage Management of ineffective cough. Alex Long Specialist NIV/Respiratory physiotherapist June 2016

Symptom Control and End of Life Care

Ratified by: Care and Clinical Policies Date: 17 th February 2016

Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.

Muscular Dystrophy UK s Adult North Star Network. Care recommendations for adults with Duchenne a consultation

Cigna Drug and Biologic Coverage Policy

Patient Sticky Label. A Resource Guide for Stroke Survivors and their Caregivers

Discuss the Process for PQRS Reporting. Explain How Often Therapists Should Report

Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis

Respiratory Surveillance and Management of plwmnd EVIDENCE BASED PRACTICE

Course Handouts & Disclosure

10th Medicine Review Course st July Prakash Kumar

Department of Physical Medicine and Rehabilitation

Subject: Edaravone (Radicava)

Guideline of Videofluoroscopic Swallowing Study (VFSS) in Speech Therapy

Rebecca Mason. Respiratory Consultant RUH Bath

Symptomatictreatments for amyotrophic lateral sclerosis/motor neuron disease(review)

Mechanical Ventilation of the Patient with Neuromuscular Disease

This is an author produced version of Clinical aspects of motor neurone disease.

Center for Optimal Aging

Painless, progressive weakness Could this be Motor Neurone Disease?

SCOTTISH MUSCLE NETWORK DUCHENNE MUSCULAR DYSTROPHY TRANSITION SOME USEFUL THINGS TO KNOW ABOUT HEALTH AROUND ADOLESCENCE

1/28/2019. OSF HealthCare INI Care Center Team. Neuromuscular Disease: Muscular Dystrophy. OSF HealthCare INI Care Center Team: Who are we?

Healthy Body, Healthy Mind

Communication and Swallowing with PSP/CBD. Megan DePuy, MBA, MS, CCC-SLP Private Speech Pathologist

CARE CONSIDERATIONS FOR DUCHENNE MUSCULAR DYSTROPHY

Dysarthria and Dysphagia: a Neurology Perspective William Meador, MD Assistant Professor of Neurology, UAB

Symptom Management in Motor Neuron Disease. Cathy Ellis MND Care & Research Centre Kings Health Partners

A PHYSIATRIC APPROACH TO PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY

Medications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center

Surgery saved my life. Rehab is restoring my future.

The Role of the Speech Language Pathologist & Spinal Cord Injury

Multiple System Atrophy

Attachment Program for Allied Health Professions in Rehabilitation Services

NICE guideline NG42 Motor neurone disease: assessment and management

The Motor Neurone Disease Association

Department of Pediatric Otolarygnology. ENT Specialty Programs

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

Palliative care. for motor neurone disease PRACTICAL NEUROLOGY

How to Effectively Manage the Motor Symptoms of HD

Western Health Specialist Clinics Access & Referral Guidelines

Juvenile Huntington s Disease

What is the next best step?

Edaravone in the Treatment of Amyotrophic Lateral Sclerosis: Efficacy and Access to Therapy A Roundtable Discussion

Parkinson s National Audit 2015

2018 KLEEFSTRA SYNDROME CONFERENCE BOSTON, MA

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/14/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Speech and Language Therapy. Kerrie McCarthy Senior Speech and Language Therapist

restoring hope rebuilding lives

Cognitive and Behavioral Changes in ALS: A Guide for People with ALS and their Families

Respiratory Care of Patients with Neuromuscular Diseases

Pediatric Patients. Neuromuscular Disease. Teera Kijmassuwan, MD Phetcharat Netmuy, B.N.S., MA Oranee Sanmaneechai, MD : Preceptor

Amyotrophic Lateral Sclerosis Performance Measurement Set

OPTICS OPTimal nutrition by Informing and Capacitating family members of best nutrition practices OPTICS

2016 Physician Quality Reporting System Data Collection Form: Sleep Apnea (for patients aged 18 and older)

Progressive Supranuclear Palsy (PSP): A Day Hospital Case Study. Mary J. Foley RGN, RNP, RANP ANP Rehabilitation Older Adult St Finbarr s Hospital

Measure #6: ALS Noninvasive Ventilation Treatment for Respiratory Insufficiency Discussed Amyotrophic Lateral Sclerosis

CONSIDERATIONS for TREATMENT RECOMMENDATIONS

Patient Stroke Recovery

Do Not Cite. For Public Comment Period DRAFT MEASURE #3: Evaluation of Pulmonary Status Ordered MUSCULAR DYSTROPHY

Oral care & swallowing

OUTCOME MEASURES IN NEUROLOGY CLINICAL TRIALS

Frailty and falls assessment and intervention tool

Palliative care Non-malignant Respiratory Disease. Scott Davidson Queen Elizabeth University Hospital Glasgow

Lexi Harlow, PT, DPT, CLT Seattle Cancer Care Alliance

Understanding Parkinson s Disease Important information for you and your loved ones

ALTRU HEALTH SYSTEM Grand Forks, ND STANDARD GUIDELINE

Y. Zhang N. Schuff S. Woolley. L. Boreta

Dr. CK NG Department of Medicine Queen Elizabeth Hospital Kowloon Central Cluster

OPTICS OPTimal nutrition by Informing and Capacitating family members of best nutrition practices OPTICS

Chapter 19. Nutrition and Fluids. All items and derived items 2015, 2011 by Mosby, Inc., an imprint of Elsevier Inc. All rights reserved.

Dysphagia Identification and Management

Welcome to todays Webinar

Chapter 12. Ataxia-Telangiectasia

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

Olesoxime for amyotrophic lateral sclerosis first line

Medical History Form

Respiratory implications of motor neurone disease

Functional Activity and Mobility

Beyond the neurologist: the importance of a multidisciplinary approach in SSA. Catherine Dotchin

Transcription:

Symptom management in ALS David Walk, M.D. Medical Director ALS Certified Center of Excellence University of Minnesota Health

Outline of today s points Overview Disease state Clinic team Assessment Functional status Ventilatory status Symptom management

ALS: overview

ALS: disease overview About 20,000 people living with ALS in the US Average age of onset about 60 About 60% of patients are men

ALS: Disease overview motor neuron disease Upper motor neuron signs Spasticity Hyperreflexia Clumsiness UMN pattern weakness Strained, strangled speech Lower motor neuron signs Flaccid tone Atrophy Weakness Fasciculations Breathy, hypophonic speech

ALS: disease overview

ALS: Disease overview Ravits, La Sapda, Neurology 2009

Cognitive and behavioral impairment: Edinburgh Cognitive Assessment domains Abrahams et al, Amyotr Lat Scler and Frontotemporal Dementia 2014;15:9-14.

ALS: a whole-brain disorder? Based on Brettschneider et al, Ann Neurol 2013;74:20-38.

ALS symptoms UMN symptoms: clumsiness, spasticity LMN symptoms: weakness, dyspnea, fasciculations Bulbar symptoms Dysarthria, sialorrhea, dysphagia, PBA Cognitive and behavioral symptoms Dysexecutive syndrome Language disorders Behavioral change

Multidimensional aspect of clinical presentation Bulbar-limb Cog-Behav UMN-LMN

American Academy of Neurology ALS Quality Measures 1. Multidisciplinary care plan 2. Disease-modifying pharmacotherapy discussed 3. Cognitive and behavioral impairment screening 4. Symptomatic therapy offered 5. Respiratory insufficiency addressed 6. NIV offered 7. Screening for dysphagia, weight loss, and impaired nutrition 8. Nutritional support offered 9. Communication support referral 10.End of life planning assistance 11.ALS falls querying

ALS multidisciplinary clinic team training Nurse MD MD PT OT SLP RD RT MSW PhD GC clinic role Care coordination neurologist pulmonologist Gait, falls, wheeled mobility, functional assessment ADLs, functional and cognitive assessment Swallowing, speech, functional and cognitive assessment Nutritional management PFTs and respiratory education Counseling, social work, help with advanced directives Counseling Genetic counseling, MDA database MDA health care services coordinator ALS Association representative

Clinical assessment

Assessment in the clinical setting: ALSFRS-R

ALSFRS-R as a guide to progression and care needs

Assessment in the clinical setting: ventilatory parameters

ALS: symptom management

Major categories of today s discussion of symptom management Bulbar and nutrition Ventilation, sleep, and energy Muscle symptoms Cognitive, behavioral, mood Pain Social and existential Not covered here: disability management: ADLs, mobility, communication

Pseudobulbar affect Dextromethorphan/Quinidine (Nuedexta) Amitriptyline Occasionally SSRIs

Sialorrhea Anticholinergics Glycopyrrolate: short acting, well-tolerated, titratable Amitriptyline: long-acting, can help with sleep, mood, and pain Atropine drops: go where the problem is Scopolamine: set it and forget it, but limited tolerance and AEs Hyoscyamine Botulinum toxin to parotids, submandibular glands No systemic AEs 3 month DUA Risk of exacerbating dysphagia Radiation therapy No systemic AEs Permanent fix

Phlegm, mucus and upper airway symptoms Possible cause Reflux Post-prandial cough due to silent aspiration Tracheobronchial secretions Excess saliva Post-nasal secretions Laryngospasm Pneumonia management Upright after meals, omeprazole Dysphagia diet, gastrostomy Manually assisted cough, cough assist, lung volume recruitment, guafenisin Saliva management ENT assessment SLP management (training) Urgent medical evaluation Not always easy to diagnose or treat!

Dysphagia Assessments Bedside assessment VFSS EAT-10 Interventions Dysphagia diet Gastrostomy

Gastrostomy Green light: FVC > 50% Yellow light: FVC 30-50% Red light: FVC < 30% RIG probably safest if no contraindications

Total daily energy expenditure estimates based upon H-B + ALSFRS-6 (only one approach to estimating caloric needs) BMR calculation for men BMR = 66 + ( 13.7 x weight in kg ) + ( 5 x height in cm ) - ( 6.76 x age in years ) BMR calculation for women BMR = 655 + ( 9.6 x weight in kg ) + ( 1.8 x height in cm ) - ( 4.7 x age in years ) TDEE = BMR from H-B equation + (55.96 x ALSFRS-6 score) -168 From Rup Tandan, M.D.

Ventilation, sleep, and energy Parameters for NIV FVC <50%, MIP < 60, or symptoms of noc ventilatory dysfunction Supine FVC, nasal insp pressure (sniff) used when applicable SaO2 < 88% rarely relevant in ALS NIV is sometimes poorly tolerated in bulbar-onset disease Try different masks, nasal pillows, daytime trials Secretion management (see above phlegm, mucus, and saliva) Poor sleep hygiene Energy conservation Exhausted after toileting, shower, dressing! Use the power w/c

Spasticity Stretching Oral baclofen Tizanidine Dantrolene Intrathecal baclofen Botulinum toxin

Cramps Vitamin E Magnesium oxide Mexiletine Hot Shot Quinine

Mood, cognitive, and behavioral problems Symptom management Depression: counseling SSRI Anxiety: SSRI benzodiazepines (caution) Behavioral: Family strategies Quetiapine Low-dose olanzapine Safety management CPT Driver s evaluation Less practical in ALS because of rate of progression Behavioral health evaluation

ALS Cognitive Behavioral Screen (ALS CBS) Woolley et al, Amyotroph Lat Scler 2010; 11:303-311. Susan Woolley

Pain Immobility musculoskeletal pain Adhesive capsulitis Neuropathic pain is uncommon

Social and existential considerations Social considerations Isolation Loss of life roles Changed relationships Am I a burden Existential considerations Life goals achieved? Quality of life? Sources of pleasure (physical/cognitive) and self-worth?

Multidisciplinary care in ALS Problem Management Expert team member Ventilatory impairment Non-invasive ventilation Respiratory therapist Tracheostomywithmechanical ventilation Pulmonologist Weak cough Manually assisted cough Long volume recruitment Mechanically assisted cough (insufflator/exsufflator) Respiratory therapist Dysarthria Augmentativecommunicationdevices Speech/language pathologist Dysphagia Sialorrhea Dietary modifications Gastrostomy Anticholinergic medications Botulinum toxin to salivary glands Radiation therapy to salivary glands Speech/language pathologist Neurologist Weight loss High-calorie, high fat diet Estimating caloric needs based upon activity Registered dietician Impaired ADLs Adaptations, equipment Occupational therapist Impaired mobility and falls Gait aids, wheelchair, power chair Physical therapist Spasticity Stretching, oral baclofen, tizanidine, dantrolene, and intrathecal baclofen Neurologist or Physical Medicine & Rehabiliation specialist Pain Physical therapy, medications Neurologist, physical therapist, pain medicine specialist Anxiety,depression, and changing life roles Counseling,medications Psychologist, Neurologist Pseudobulbar affect dextromethorphan/quinidine(nuedexta ), amitriptyline Neurologist Cognitiveandbehavioral impairment, dementia Screening instruments, diagnostic instruments, safety evaluations Occupational therapist, neuropsychologist Life planning Financial counseling, advanceddirective, POLST Social worker, attorney, neurologist Clinical research Discussion, on-line resources Neurologist, research coordinator, patient advocacy group representative

Thank you